Unternehmen wird geladen
Keep exploring
The themes Indivior Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited34,4B $A
NBIXNeurocrine Biosciences, Inc.16,9B $A+
ELANElanco Animal Health Incorporated13,4B $A
KNSAKiniksa Pharmaceuticals International, plc8,2B $A+
LQDALiquidia Corporation5,2B $A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28. Okt. 2026CAGraded C, now A
Womit das Unternehmen Geld verdient
- SUBLOCADE monthly buprenorphine injections74 %
- Sublingual buprenorphine medicines25 %
Die Umsatzanteile sind Schätzungen für six months ended June 30, 2026 und keine Zahlen aus einem eingereichten Bericht.
Konkurriert mit
- CAMXCamurus
- Braeburn
- ALKSAlkermesC
- Größe
- 7,9B $
- Marge
- -0,0 %
Was es verkauft4
SUBLOCADE
An extended-release buprenorphine injection given under the skin once a month by a health care professional to treat OUD.
SUBOXONE Film
A film containing buprenorphine and naloxone that dissolves under the tongue or against the inside of the cheek to treat OUD.
SUBUTEX Tablet
A buprenorphine tablet that dissolves under the tongue to treat OUD; sold mainly in Australia, France and Germany.
SUBOXONE Tablet
A buprenorphine-and-naloxone tablet for OUD that Indivior continues to sell on a limited transition basis in some countries.
Wer es kauft4
- Pharmaceutical wholesalers buy medicines from Indivior and distribute them to pharmacies, hospitals and other health care customers; its three largest customers together accounted for 51% of global net revenue (2025, high).
- Specialty pharmacies and distributors handle medicines that require controlled storage or delivery, including SUBLOCADE.
- Hospitals, addiction treatment centers and other organized health systems purchase or arrange access to medicines for patients receiving care.
- Government and private health insurers reimburse for treatment, while health care professionals prescribe or administer the medicines.
Worauf es steht, und was es umwerfen könnte
Wovon das Geschäft abhängt
- 1SUBLOCADE accounted for 74% of net revenue (six months ended June 30, 2026, high), making sales dependent on that product.
- 2The United States accounted for 85% of net revenue (2025, high).
- 3Indivior makes the buprenorphine active ingredient at its Hull, United Kingdom plant, but relies on Curia to manufacture SUBLOCADE.
- 4Aquestive is the exclusive global manufacturer and primary packager of SUBOXONE Film.
- 5The three largest U.S. wholesale customers accounted for 51% of global net revenue (2025, high).
Was schiefgehen könnte
- 1Sales depend heavily on SUBLOCADE; competing long-acting buprenorphine medicines and generic competition for other products could reduce sales or put pressure on prices.
- 2Reliance on outside manufacturers and packagers creates a risk that production or regulatory problems could interrupt supply; buprenorphine supply also depends on controlled-substance import and distribution rules.
- 3Changes to insurance coverage, government reimbursement or rules for controlled medicines could limit patient access or reduce what Indivior receives for its medicines.
Über Indivior Pharmaceuticals, Inc.
Indivior makes prescription medicines for opioid use disorder (OUD), a condition involving harmful opioid use. Its main product, SUBLOCADE, is a monthly injection given by a health care professional; other medicines dissolve under the tongue or inside the cheek. The company sells mainly in the United States, with sales also in Canada, Australia, France and Germany.
- Hauptsitz
- Richmond, Virginia, United States
- Gegründet
- 2014
- Notiert an
- Nasdaq
- Geschäftsjahresende
- December 31
Gebaut aus den eigenen Einreichungen von Indivior Pharmaceuticals, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
